Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (16,480,817)	$ (24,396,828)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,343,859	3,328,344
Interest accrued on note receivable	(82,895)
Change in fair value of note receivable	114,870
Write-off of construction-in-process	747,348
Depreciation and amortization	371,814	267,311
Changes in operating assets and liabilities:
Receivable due from collaboration agreement		(184,272)
Research and development tax incentive receivable	(211,785)	(103,307)
Prepaid assets and other current assets	1,416,302	1,433,966
Accounts payable	66,910	148,657
Accrued compensation	(4,430)	(416,910)
Deferred revenue	(50,000)	312,710
Operating lease obligation	(55,764)	(29,869)
Net cash used in operating activities	(11,824,588)	(19,640,198)
Cash flows from investing activities:
Purchases of property and equipment	(48,359)	(1,410,159)
Net cash used in investing activities	(48,359)	(1,410,159)
Cash flows from financing activities:
Sale of common stock in public offering, net of offering costs	5,064,722
Sale of common stock through ATM, net of offering costs	25,272	404,555
Payment of offering costs in connection with ATM	(77,149)
Proceeds from issuance of common stock for stock option exercises		10,185
Net cash provided by financing activities	5,012,845	414,740
Effect of exchange rate changes on cash and cash equivalents	(26,458)	(11,965)
Net change in cash and cash equivalents	(6,886,560)	(20,647,582)
Cash and cash equivalents at beginning of period	16,612,315	33,794,672
Cash and cash equivalents at end of period	9,725,755	13,147,090
Supplemental disclosure of non-cash investing and financing activities:
Receivable for option exercise		100,637
ROU asset obtained for new operating lease		$ 238,021